Predicting the mechanism of phospholipidosis

Robert Lowe¹, Hamse Y Mussa¹, Florian Nigsch², Robert C Glen¹ and John BO Mitchell³*

Abstract
The mechanism of phospholipidosis is still not well understood. Numerous different mechanisms have been proposed, varying from direct inhibition of the breakdown of phospholipids to the binding of a drug compound to the phospholipid, preventing breakdown. We have used a probabilistic method, the Parzen-Rosenblatt Window approach, to build a model from the ChEMBL dataset which can predict from a compound’s structure both its primary pharmaceutical target and other targets with which it forms off-target, usually weaker, interactions. Using a small dataset of 182 phospholipidosis-inducing and non-inducing compounds, we predict their off-target activity against targets which could relate to phospholipidosis as a side-effect of a drug. We link these targets to specific mechanisms of inducing this lysosomal build-up of phospholipids in cells. Thus, we show that the induction of phospholipidosis is likely to occur by separate mechanisms when triggered by different cationic amphiphilic drugs. We find that both inhibition of phospholipase activity and enhanced cholesterol biosynthesis are likely to be important mechanisms. Furthermore, we provide evidence suggesting four specific protein targets. Sphingomyelin phosphodiesterase, phospholipase A2 and lysosomal phospholipase A1 are shown to be likely targets for the induction of phospholipidosis by inhibition of phospholipase activity, while lanosterol synthase is predicted to be associated with phospholipidosis being induced by enhanced cholesterol biosynthesis. This analysis provides the impetus for further experimental tests of these hypotheses.

Background
Since the observation of phospholipidosis by Nelson and Fitzhugh in 1948 [1], many attempts have been made at understanding the underlying mechanism(s) [2,3]. Phospholipidosis is the excess accumulation of phospholipids induced in several cell types by numerous cationic amphiphilic drugs (CADs). The most reliable way of determining whether a compound has induced phospholipidosis is by electron microscopy. This analysis is important in the drug development process where the occurrence of phospholipidosis can cause delays and possibly termination of a project (as more tests need to be carried out to satisfy regulatory bodies). It is still unclear whether an accumulation of phospholipids is harmful to human health [4], the process is often reversible upon withdrawal of the compound, and despite attempts to understand the mechanism of phospholipidosis there is still no mechanistic understanding of how CADs can induce the accumulation of phospholipids in various cell types across different species.

A build-up of phospholipids can be explained by an inhibition of the breakdown or an increase in the synthesis of the phospholipids. Early studies supported the idea that inhibition of the breakdown of phospholipids was a possible mechanism. Hostetler et al. [2] showed strong support for the theory that the action of CADs was located in the lysosomes and that inhibition of the lysosomal phospholipases A and C caused a build-up of phospholipids. However, there was no way to distinguish between a drug-enzyme or drug-phospholipid binding event as the cause of the inhibition. Joshi et al. [5] tried to address this problem by measuring binding of phospholipidosis-inducing drugs to L-α-dipalmitoyl phosphatidylcholine vesicles. This suggested that if a drug was found to bind, then drug-phospholipid binding would be the cause of the inhibition of the phospholipases. While most of the drugs tested did bind to L-α-dipalmitoyl phosphatidylcholine vesicles, chloroquine (a phospholipidosis-inducing CAD) did not bind, suggesting that its main mechanism is the direct inhibition of one or more phospholipase enzymes. Abe et al. [6] produced the first study that distinguished between lysosomal...
phospholipases A1 and A2. This showed that two CADs, amiodarone and D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, caused inhibition of lysosomal phospholipase A2. They found that no inhibition occurred on exposure to tetracycline, despite its being a CAD. Hirode et al. [7], however, found evidence that at high doses tetracycline may induce phospholipidosis. Further studies on lysosomal phospholipase A2 inhibition by CADs have been performed in which Hiraoka et al. [3] used lysosomal phospholipase A2 (LYPLA2)-deficient mice to study the relationship between LYPLA2 and phospholipidosis. A deficiency of the enzyme resulted in foam cell formation, surfactant lipid accumulation, splenomegaly (enlargement of the spleen), and phospholipidosis. A smaller number of studies have also looked at the possibility of increased synthesis of phospholipids being the mechanism for phospholipidosis by showing that an increase or redirection of synthesis leads to increased amounts of acidic phospholipids [8,9].

Reasor et al. [4] produced a review on the subject suggesting that no single underlying mechanism covers all phospholipidosis-inducing compounds. Phospholipidosis is not organ specific [10], however, it can be species specific where certain drugs cause phospholipidosis in one species and not in another. This implies that the mechanism for phospholipidosis may be highly complex and species dependent. Sawada et al. [11] recently summarised four possible mechanisms suggested by their toxicogenomics experiments:

1. Inhibition of lysosomal phospholipase activity;
2. Inhibition of lysosomal enzyme transport;
3. Enhanced phospholipid biosynthesis;
4. Enhanced cholesterol biosynthesis.

Attempts have been made to predict the occurrence of phospholipidosis using in silico methods. Ploemen et al. [12] suggested that a compound would be phospholipidosis-inducing (PPL+) provided that it has pK_a > 8 and ClogP > 1 and that the sum of the squares (ClogP^2 + pK_a^2) is greater than 90, showing that ClogP and pK_a are important descriptors. Other authors have developed increasingly sophisticated models, introducing more complicated Quantitative Structure-Property Relationship (QSPR) methods and descriptors [13-15].

In this study, our aim is to use an in silico approach to predict the possible targets that may be relevant for phospholipidosis. By predicting the targets for a database of phospholipidosis-inducing compounds, we can rank targets by their potential to cause phospholipidosis and compare them to targets previously suggested.

The study of off-target interactions, known as secondary pharmacology, is now recognised as crucial to the understanding of both drug action and toxicology. In favourable cases, one drug may modulate plural disease-relevant targets, a property known as polypharmacology. More commonly, off-target interactions present the risk of side-effects, as is the case with phospholipidosis. Given the prevalence, expense, and risk to patients associated with unforeseen side-effects related to drug-target interactions, studies in this area have particular relevance to the pharmaceutical industry.

This study uses a methodology more complex than many seen in cheminformatics. Our objective is not simply to appeal to the similar property principle. A prediction based on that would run something like this: molecule B is similar to molecule A, which induces phospholipidosis, hence we predict that molecule B induces phospholipidosis too. Here, by way of contrast, we are interested in teasing out a mechanistic understanding of phospholipidosis and in suggesting and informing experimental approaches directed towards gaining a deeper mechanistic understanding.

Materials and methods

The ChEMBL database [16] was mined for compounds and their related protein targets. A number of rules were used to filter the dataset. Only compounds which had an associated structure were selected. If the target description included the word “enzyme”, “cytosolic”, “receptor”, “agonist” or “ion channel” and the bioactivity record of the compound contained an IC50, K_i or K_d < 500 μM or had an activity > 50% binding affinity, then it was selected. Of course, we recognise that differences between these measures may sometimes be significant; for instance, K_i and K_d are not strictly equivalent quantities. This selection process produced a dataset which consisted of compounds and their corresponding targets, where a compound may be related to more than one target. A relatively high IC50, K_i or K_d threshold was used as the aim of the study is to look at off-target prediction and therefore potentially weak binding targets. This approach selected a total of 249358 compounds which are related to a total of 3493 different targets. A further stipulation was that for a target to be present in the dataset it must have at least 20 compounds associated with it. This reduced the total dataset to 241145 compounds with 1923 different targets. In other words, the procedure yields N (= 241145) molecules belonging to M (= 1923) classes.

In the following discussion, the molecules are represented by pattern vectors (descriptors) x_j of dimension d with j = 1, 2, ..., N; ω_a_x denotes the classes with a = 1, 2, ..., M. In this work the descriptors used for the molecules were circular fingerprints [17]. To build a predictive model, the Parzen-Rosenblatt Window method [18] was used as the basis of a multi-class classification
algorithm. For each possible class \( \omega_{\alpha r} \) we used the Parzen-Rosenblatt Window scheme to estimate the average similarity of the test molecule \( x_i \) to the training set molecules in that class (say) \( x_j \in \omega_{\alpha r} \) with similarity being measured by the kernel function \( K(x_i, x_j) \) as

\[
S'_{\alpha r} = \frac{1}{N_{\alpha r}} \sum_{x_i \in \omega_{\alpha r}} K(x_i, x_j),
\]

where \( N_{\alpha r} \) denotes the number of the training data instances belonging to class \( \omega_{\alpha r} \) and the kernel function is as defined below. We wish to rank the classes for each compound according to our best estimates of the class probabilities \( p(\omega_{\alpha r} | x_i) \), the probabilities of the molecule being associated with each specific protein target. From Bayes’ theorem, we can relate \( p(\omega_{\alpha r} | x_i) \) to \( p(x_i | \omega_{\alpha r}) \), the class-condition probability density (mass) function for molecule \( x_i \) given that it comes from class \( \omega_{\alpha r} \), as follows:

\[
p(\omega_{\alpha r} | x_i) = \frac{p(x_i | \omega_{\alpha r})p(\omega_{\alpha r})}{p(x_i)}
\]

Since, for a given molecule, \( p(x_i) \) takes a constant value for all classes, ranking the classes by \( p(\omega_{\alpha r} | x_i) \) is equivalent to ranking them according to the product \( p(\omega_{\alpha r})p(x_i | \omega_{\alpha r}) \). This is a convenient approach, since both \( p(\omega_{\alpha r}) \) and \( p(x_i | \omega_{\alpha r}) \) are relatively easy to estimate. We take \( p(x_i | \omega_{\alpha r}) \) to be equal to the proportion of training set molecules belonging to that class, given by \( N_{\omega_{\alpha r}}/N \). It is assumed that \( p(x_i | \omega_{\alpha r}) \) is directly proportional to \( S'_{\alpha r} \), the measure of average similarity, as described in equations 1 and 3

\[
p(x_i | \omega_{\alpha r}) = \frac{1}{N_{\alpha r}} \sum_{x_j \in \omega_{\alpha r}} K(x_i, x_j).
\]

As well as the top-ranked class, effectively a prediction of the primary pharmaceutical target of a drug, we are equally interested in lower ranked predictions corresponding to off-target interactions potentially causing side-effects. We choose the Gaussian kernel

\[
K(x_i, x_j) = \frac{1}{(2\pi h^d)^N} \exp \left( -\frac{(x_i - x_j)^T(x_i - x_j)}{2h^2} \right),
\]

where \((x_i - x_j)^T(x_i - x_j)\) corresponds to the number of features in which \( x_i \) and \( x_j \) disagree, while \( h \) is the so-called smoothing factor. In the scenario where equal probabilities are calculated for two classes, \( p(\omega_{\alpha r})p(x_i | \omega_{\alpha r}) = p(\omega_{\alpha r})p(x_i | \omega_{\alpha r}) \), these classes are ranked arbitrarily.

The mined ChEMBL dataset was partitioned into ten randomly split training and validation partitions, the size of which was determined by 99% of each class being present in the training and 1% in the validation set. For classes with fewer than 100 instances, a single instance was present in the validation and the rest in the training set. This produces a training data set with 238086 compounds and a validation set of 3059 compounds for each of the ten partitions. The Parzen-Rosenblatt Window method was applied to each of the ten splits with the smoothing factor \( h \) being varied according to \( 2^{-15}, 2^{-11}, \ldots, 2^3 \). We also carried out analogous calculations using the Naïve Bayes method, implemented as described in reference [19], allowing us to compare the results from these two techniques.

The ten different models produced on the ten different training partitions were then used to predict the targets of a phospholipidosis dataset with the Parzen-Rosenblatt Window method. The dataset consists of 182 compounds (100 are positive (PPL+)) for phospholipidosis and 82 are negative (PPL-)) with a label indicating whether a compound is positive and induces phospholipidosis or is labelled negative and is experimentally confirmed to not induce it. We emphasise that all positives and negatives in our data are experimentally confirmed as such; there are no unverified assumed negatives. The data were primarily derived from Pelletier et al. [14], with a number of additional molecules taken from other literature sources such as [20], and are almost identical to the dataset we used in [15]. The full dataset is presented as Additional File 1. We note that an instance is a compound-target relation and not simply a compound, so another target association of a compound from the phospholipidosis dataset may appear in our training set. As we are interested in obtaining as comprehensive as possible a set of targets for these compounds, the other known compound-target relations were not removed from the training set. Our approach allows experimentally known associations of these 182 compounds with other targets, not directly relevant to phospholipidosis, to contribute to our predictions. From the targets predicted for each compound, the top 100 were used as this corresponds to approximately 5% of the total targets. As we are interested in off-targets, the order in which the targets were predicted for each compound is of limited interest here and hence a scoring system was designed to account for this. For the phospholipidosis dataset we have a label, \( c_p \), which represents whether a compound, \( x_i \), is PPL+ (\( c_p(x_i) = +1 \)) or PPL- (\( c_p(x_i) = -1 \)). For each target, \( \omega_{\alpha r} \), we calculate the phospholipidosis score \( PS_{\alpha r} \) using equation (5):

\[
PS_{\alpha r} = \sum_{i=1}^{N} C_p(x_i)\delta(\omega_{\alpha r})
\]

where \( \delta(\omega_{\alpha r}) = 1 \) if \( \omega_{\alpha r} \) is in the top 100 predictions or 0 otherwise, and \( N \) is the total number of compounds in
the phospholipidosis dataset. The $PS_\alpha$ score reported is a sum over the ten different models. A diagrammatic overview of our methodology is given in Figure 1.

**Results**

The output recorded from the prediction of the validation compounds was the rank order of classes based on their estimated values of the product $p(o_\alpha) \times p(x_i | o_\alpha)$. The class with the highest probability was given a rank of 1, the second highest a rank of 2 and so on. To calculate the optimum smoothing parameter, the arithmetic mean of the rank of the actual class for the validation set was calculated. The smoothing factor $h = 2^{-3}$ produces the top average rank compared to the other smoothing factors tried and hence was used for the rest of the paper. Table 1 shows the arithmetic mean of the predicted ranks of actual experimentally known classes, calculated across the ten validation partitions with this smoothing parameter. Since this Table measures the prediction performance of our machine

![Figure 1 Study methodology](image)

**Table 1** Comparison of the Parzen-Rosenblatt Window and Naïve Bayes methods

| Partition No. | PRW Rank | NB Rank |
|---------------|----------|---------|
| 1             | 17.049   | 74.104  |
| 2             | 16.343   | 76.251  |
| 3             | 18.424   | 79.078  |
| 4             | 16.212   | 73.539  |
| 5             | 17.339   | 73.535  |
| 6             | 18.630   | 77.244  |
| 7             | 20.069   | 78.560  |
| 8             | 18.870   | 74.464  |
| 9             | 16.584   | 76.235  |
| 10            | 18.200   | 78.077  |
| **Average**   | **17.835** | **76.109** |

Average ranks of known targets as predicted in the 10-fold cross-validation by the Parzen-Rosenblatt Window [18] and by a Naïve Bayes method [19]. The Parzen-Rosenblatt Window, using $h = 2^{-3}$, consistently assigns better ranks to the known targets, its predicted ranks being numerically smaller by a factor of 4.3.
learning method, we excluded all data for validation compounds from the respective training sets. We also calculated predicted ranks in an exactly analogous way by 10-fold cross-validation using the Naïve Bayes method; these results are also shown in Table 1. The Parzen-Rosenblatt Window consistently assigns better ranks to the known targets, its predicted ranks being numerically smaller by a factor of 4.3. The calculated p-value of \( p = 2.889 \times 10^{-15} \) confirms that at the 5% significance level the mean of the average rank from the Parzen-Rosenblatt Window is statistically significantly smaller than the mean of the average rank from Naïve Bayes. Hence, we did not consider Naïve Bayes further and used only the Parzen-Rosenblatt Window in the phospholipidosis part of the study.

Table 2 shows the top 20 scoring targets and their phospholipidosis scores \( PS_a \). The \( PS_a \) score is the total score for a target across all 182 compounds over the ten models derived from the ten different partitions of the ChEMBL dataset. A large number of the targets that score highly are CNS (central nervous system) type targets, such as the sodium-dependent serotonin transporters, dopamine receptors and serotonin receptors, which are often the primary pharmaceutical targets of CADs.

### Table 2 Top 20 \( PS_a \) scores for targets

| Rank | Name | \( PS_a \) |
|------|------|----------|
| 1    | S-hydroxytryptamine receptor 2B (r) | 444 |
| 2    | S-hydroxytryptamine receptor 2C (r) | 443 |
| 3    | D(2) dopamine receptor (r) | 436 |
| 4    | S-hydroxytryptamine receptor 1A (r) | 409 |
| 5    | Potassium voltage-gated channel subfamily H member 2 (h) | 406 |
| 6    | Sodium-dependent serotonin transporter (r) | 394 |
| 7    | D(3) dopamine receptor (r) | 385 |
| 8    | D(3) dopamine receptor (h) | 385 |
| 9    | Muscarinic acetylcholine receptor M5 (r) | 379 |
| 10   | Alpha-1D adrenergic receptor (r) | 376 |
| 11   | Alpha-1A adrenergic receptor (r) | 371 |
| 12   | Alpha-1B adrenergic receptor (r) | 369 |
| 13   | S-hydroxytryptamine receptor 2A (r) | 367 |
| 14   | Sodium-dependent serotonin transporter (h) | 357 |
| 15   | S-hydroxytryptamine receptor 1B (r) | 357 |
| 16   | Transporter (r) | 350 |
| 16   | Muscarinic acetylcholine receptor M1 (r) | 350 |
| 18   | Sodium-dependent dopamine transporter (r) | 349 |
| 19   | Sigma 1-type opioid receptor (h) | 348 |
| 20   | Sodium channel protein type 2 subunit alpha (h) | 347 |

List of the top 20 targets ranked by their \( PS_a \) scores across all 182 compounds over the ten models derived from the ten different partitions of the ChEMBL dataset. A higher \( PS_a \) score suggests more phospholipidosis positive than negative compounds are associated with the target. A large number of the highly placed targets in our \( PS_a \) rankings are the intended drug targets of CADs. Each of the top 20 targets comes from either human (h) or rat (r). Tied ranks are denoted by =.

The \( PS_a \) scores for all 1923 targets are given in Additional File 2.

### Discussion

The average ranks of the actual targets in the validation set in Table 1 show that the models are on average able to predict the correct target in the top 1%. This suggests that using high IC50, \( K_d \) and \( K_a \) values, which correspond to low activity, to select the dataset still allows for good predictive models and hence that it is possible to predict weak binding. If the cut-off is increased to the top 5% of targets, then an increase is seen from 96.1% of the actual targets being present amongst those predicted to 98.8%. It was therefore decided to use the top 5% of targets (actually 100/1923) for the phospholipidosis dataset prediction. Using this higher number allows for more of the off-targets to be selected; as the top predicted targets will often be the intended drug target of the cationic amphiphilic drug (CAD) or targets closely related to it.

None of the expected phospholipidosis-relevant targets appear in the top 20 ranked targets using the \( PS_a \) score. The highest scoring target that had been previously suggested was lanosterol synthase (LSS), which is in a tie for rank 114. A large number of the highly placed targets in our \( PS_a \) rankings are the intended drug targets of CADs, which can be used as antiarrhythmics, \( \alpha \)-blockers and antipsychotics targeting ion channel transporters (such as sodium-dependent serotonin transporter) [21], as well as D2/D3 dopamine and serotonin receptors [10]. We also note that a number of the targets are within the same protein family and hence these fill a large number of the higher ranked positions.

Importantly for our work, consideration of known biochemical function allows us to link predicted targets to particular mechanisms of inducing phospholipidosis. Sawada et al. [11] previously suggested a number of genes relevant to each of their proposed mechanisms and Table 3 shows the ranks of some of the related targets according to their \( PS_a \) scores. We also note that muscarinic acetylcholine receptors M1, M3 and M5 up-regulate phospholipase C, which if inhibited directly can lead to phospholipidosis. Therefore it could be expected that inhibition of the appropriate muscarinic acetylcholine receptors could lead to decreased production of phospholipase C and hence phospholipidosis by a more complex variant of mechanism 1. The M5 and M1 receptors appear amongst the top 20 ranked targets in 9th and joint 16th positions, respectively; M3 is ranked joint 32nd. Since they were not part of any of our original mechanistic hypotheses based on Sawada et al.’s work, however, we exclude the M1, M3 and M5 receptors from the discussion which follows.
Table 3 shows the ranked positions of the various targets predicted by Sawada et al. Sphingomyelin phosphodiesterase (SMPD) is responsible for the breakdown of sphingomyelin into phosphocholine and ceramide. Inhibition of SMPD would cause accumulation of the phospholipid sphingomyelin. A build-up of sphingomyelin is associated with Niemann-Pick disease which is often linked to phospholipidosis [22]. Lysosomal phospholipase A2 (LYPLA2) has previously been linked with phospholipidosis, however, due to the lack of data in ChEMBL it was not present in the model. Only two compounds have an associated binding affinity with this target and hence the target did not meet the requirement of having data for at least 20 compounds. LYPLA1 and phospholipase A2 (PLA2) were present in the model and produced \(P_{S_a}\) scores of 90 and 97, respectively. We expect that lysosomal phospholipase A2 would produce a similar score. Both of these targets act by breaking down phospholipids and hence are shown in Table 3 as being associated with mechanism 1. Since there are no relevant targets present in the original training data, it is not possible to comment on the likelihood of mechanism 2. However, it is clear that our model predicts that the induction of phospholipidosis via the mechanism 3 targets ELOVL6 or SCD is unlikely, as neither is predicted to interact with any of the 100 positive phospholipidosis-inducing compounds. For mechanism 4, out of the targets included in our model, lanosterol synthase produced the best result of those related to Sawada et al.’s mechanisms. Lanosterol synthase is involved in steroid biosynthesis, catalysing the cyclisation of (S)-2,3 oxidosqualene to lanosterol; hence it is associated with enhanced cholesterol biosynthesis (mechanism 4).

Since three targets for mechanism 1 and one for mechanism 4 score highly, our results suggest that a combination of mechanisms 1 and 4 is responsible for inducing phospholipidosis. Thus we find support, from an independent source of evidence and a quite different methodology, for two of the four mechanisms (1 & 4) which Sawada et al. proposed on the basis of their gene expression experiments. A lack of data for suitable targets meant that we could not test any targets for their mechanism 2, while our study suggests that their mechanism 3 does not occur via the targets ELOVL6 or SCD. Our method can only predict drug-protein associations and cannot predict whether phospholipidosis will occur via drug-phospholipid binding. Therefore it can only predict a mechanism which involves direct interaction with the protein.

Table 3 shows the combined rankings of the various targets and their corresponding \(P_{S_a}\) scores. The table includes the targets for each mechanism, their ranks, and \(P_{S_a}\) scores. The targets are grouped into their different mechanisms: 1) Inhibition of phospholipase activity; 2) Inhibition of lysosomal enzyme transport (not represented in this table); 3) Enhanced phospholipid biosynthesis; 4) Enhanced cholesterol biosynthesis. While Sawada et al. worked with human hepatoma HepG2 cells, (11) we also consider the corresponding genes in other species. Where homologous ChEMBL targets from two species were part of our model, for instance both human and rat versions of lanosterol synthase appeared, the higher scoring one is listed in this table; all its entries are from human (h), rat (r) or mouse (m).

Table 3. \(P_{S_a}\) scores and ranks for phospholipidosis-relevant targets

| Mechanism | Target | Rank | \(P_{S_a}\) |
|-----------|--------|------|-----------|
| 1         | Sphingomyelin phosphodiesterase (SMPD) (h) | 225 | 55 |
|           | Lysosomal Phospholipase A1 (LYPLA1) (r) | 163 = 90 |
|           | Phospholipase A2 (PLA2) (h) | 152 = 97 |
| 3         | Elongation of very long chain fatty acids protein 6 (ELOVL6) (h) | 1205 = -10 |
|           | Acyl-CoA desaturase (SCD) (m) | 610 = 0 |
| 4         | 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) (h) | 456 = 10 |
|           | Squalene monoxygenase (SQLE) (h) | 437 = 14 |
|           | Lanosterol synthase (LSS) (h) | 114 = 134 |

Table of the targets suggested by Sawada et al. [11] which are included in our model and their ranks based on the \(P_{S_a}\) score; tied ranks are denoted by =. The targets are grouped into their different mechanisms: 1) Inhibition of phospholipase activity; 2) Inhibition of lysosomal enzyme transport (not represented in this table); 3) Enhanced phospholipid biosynthesis; 4) Enhanced cholesterol biosynthesis. While Sawada et al. worked with human hepatoma HepG2 cells, (11) we also consider the corresponding genes in other species. Where homologous ChEMBL targets from two species were part of our model, for instance both human and rat versions of lanosterol synthase appeared, the higher scoring one is listed in this table; all its entries are from human (h), rat (r) or mouse (m).
anti-correlation, suggests that different compounds induce phospholipidosis via each of these two targets, which are associated with different mechanisms. We have also investigated the correlation between scores for other pairs of targets; the independence of scores between SMPD and LYPLA1 has an associated p-value of 0.507, and hence at the 5% level the null hypothesis that they are independent is not rejected. The Pearson correlation coefficient was calculated to be -0.247, suggesting that LYPLA1 and SMPD are anti-correlated.

Thus our results suggest that there is strong statistical evidence that no single target or even mechanism is responsible for phospholipidosis. We find that both inhibition of phospholipase activity and enhanced cholesterol biosynthesis are likely to be important mechanisms. Furthermore, this study provides evidence that sphingomyelin phosphodiesterase, phospholipase A2 and lysosomal phospholipase A1 are all likely targets for the induction of phospholipidosis by inhibition of phospholipase activity, while lanosterol synthase is expected to be associated with phospholipidosis occurring due to enhanced cholesterol biosynthesis. With these four targets, LSS, PLA2, LYPLA1, SMPD, and even the possible additional inclusion of muscarinic acetylcholine receptors M1, M3 and M5, we cannot account for all of the phospholipidosis-inducing compounds. Hence, we suspect that either more targets are involved or that compounds may induce phospholipidosis not only by interacting with protein targets, but also by binding to the lipid itself. An overview of the predicted mechanisms is presented in Figure 3.

Conclusions
Using the Parzen-Rosenblatt Window method, predictive models of protein target associations were constructed based on compound structures. For our validation set, experimentally known targets were ranked (on average) in the top 1% of predicted targets. When applied to a dataset
Phospholipidosis score, lanosterol synthase all score highly according to our phosphatidate, lysosomal phospholipase A1, phospholipase A2 and linked to phospholipidosis. Sphingomyelin phosphodiesterases, it was found that a number of targets may be phospholipidosis-inducing and non-inducing compounds. Sphingomyelin phosphodiesterase, lysosomal phospholipase A1, phospholipase A2 and lanosterol synthase all score highly according to our phospholipidosis score, $PS_a$. It was shown that predicted activities against different targets are often uncorrelated or even anti-correlated. More simply put, different phospholipidosis-inducing compounds are predicted to interact with different putative phospholipidosis-relevant targets. This strongly suggests that different compounds induce phospholipidosis via different targets, and therefore also by different mechanisms. We note that, considering only the four different targets found to be significant here, there remain a number of PPL+ compounds for which a relevant target cannot be identified. This may indicate that further protein targets are mechanistically relevant, or that binding of the compound directly to the lipid is a possible mechanism.

Additional material

Additional file 1: The phospholipidosis dataset of 182 compounds. We present the names, SMILES strings and phospholipidosis-inducing status of the 182 molecules; the file is in .xls format.

Acknowledgements

HYM and RCG would like to thank Unilever for financial support. RL and JBOM would like to thank the EPSRC (Grant EP/F049102/1) and the Scottish Universities Life Sciences Alliance (SULSA) for funding. FN thanks the Education Office of the Novartis Institutes for Biomedical Research for a Presidential Postdoctoral Fellowship. We acknowledge the use of the CamGrid service in carrying out this work.

Author details

1. Unilever Centre for Molecular Sciences Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK. 2. Chemical Biology Informatics, Quantitative Biology, Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, 220 Massachusetts Avenue, 02139, Cambridge MA, USA. 3. Biomedical Sciences Research Complex and EaStCHEM School of Chemistry, Purdie Building, University of St Andrews, North Haugh, St Andrews, Scotland KY16 9ST, UK.

Authors’ contributions

RL wrote the software and carried out the calculations reported in this paper. JBOM, RL and FN jointly conceived the original idea and plan for this study. RL, HYM and RCG together developed the mathematical methodology used in this work. FN carried out preliminary computations upon which this work builds. RCG and JBOM provided regular supervisory input throughout the course of this work. RL wrote the original draft of the paper. All authors were closely involved in refining the manuscript and all read and approved the final version.

Competing interests

The authors declare that Robert Glen is a consultant with Unilever and Eisai and on the Board of Lhasa Ltd, and that there are no other conflicts of interest.

Received: 4 November 2011 Accepted: 26 January 2012 Published: 26 January 2012

References

1. Nelson A, Frithugh O: Chloroquine: Pathological changes observed in rats which for two years had been fed various proportions. Arch Pathol 1948, 45:454-462.
2. Hostetler K, Matsuura Y: Studies on the mechanism of drug-induced lipidosis: Cationic amphiphilic drug inhibition of lysosomal phospholipases A and C. Biochem Pharmacol 1981, 30:121-1126.
3. Hintia M, Abe A, Lu Y, Yang K, Han X, Gross RW, Shayan JA: Lysosomal Phospholipase A2 and Phospholipidosis. Mol Cell Bioi 2000, 26:6139-6148.
4. Reator MJ, Kacow S: Drug-Induced Phospholipidosis: Are There Functional Consequences? Exp Biol Med 2001, 226:625-830.
5. Joshi U, Kodavanti P, Coudert B, Dwyer T, Mehtendal H: Types of interaction of amphiphilic drugs with phospholipid vesicles. J Pharmacol Exp Ther 1988, 246:150-157.
6. Abe A, Hiraoka M, Shayan JA: A role for lysosomal phospholipase A2 in drug induced phospholipidosis. Drug Metab Lett 2007, 1:49-53.
7. Hirobe M, Ono A, Miyagishima T, Nagao T, Ohno Y, Unishidani T: Gene expression profiling in rat liver treated with compounds inducing phospholipidosis. Toxicol Appl Pharmacol 2008, 229:290-299.
8. Eichberg J, Gates J, Hauser O: The mechanism of modification by propanolol of the metabolism of phosphatidyl-CMP (CDP-diacylglycerol) and other lipids in the rat pineal gland. Biochem Biophys Acta 1978, 573:90-106.
9. Pappu A, Hostetler KY: Effect of cationic amphiphilic drugs on the hydrolysis of acidic and neutral phospholipids by liver lysosomal phospholipase A. Biochem Pharmacol 1984, 33:1639-1644.
10. Halliwell WH: Cationic Amphiphilic Drug-Induced Phospholipidosis. Toxicol Pathol 1997, 25:53-60.
11. Sawada H, Takami K, Asahi S: A toxicogenomic approach to drug-induced phospholipidosis: Analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci 2005, 83:282-292.
12. Ploemen JPP, Kelder J, Hafmans T, van de Sandt H, van Burgsteden JA, Salemink PJ, van Esch E: Use of physicochemical calculation of pKa and ClogP to predict phospholipidosis-inducing potential: A case study with structurally related piperazines. Exp Toxicol Pathol 2004, 55:347-355.
13. Tomizawa K, Sugino K, Yamada H, Horii I: Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential. J Toxicol Sci 2006, 31:315-324.
14. Pelletier DJ, Gehlhaar D, Tilloy-Ellul A, Johnson TO, Greene N: Evaluation of a Published in Silico Model and Construction of a Novel Bayesian Model for Predicting Phospholipidosis Inducing Potential. J Chem Inf Model 2007, 47:1196-1205.
15. Lowe R, Glen RC, Mitchell JBO: Predicting Phospholipidosis Using Machine Learning. Mol Pharmaceutics 2010, 7:1708-1718.
16. Warr WA: Chembl. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). J Comput Aided Mol Des 2009, 23:195-198.
17. Glen RC, Bender A, Arnborg CH, Carlsson L, Boyer S, Smith J: Circular Fingerprints: Flexible molecular descriptors with applications from physical chemistry to ADME. iDrugs 2006, 9:199-204.
18. Parzen E: On Estimation of a Probability Density Function and Mode. Annals of Mathematical Statistics 1962, 33:1065-1076.
19. Nigsch F, Bender A, Jenkins JL, Mitchell JBO: Ligand-Target Prediction using Winnow and Naive Bayesian Algorithms and the Implications of Overall Performance Statistics. J Chem Inf Model 2008, 48:2313-2325.
20. Kruhlik NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancillo LF: Development of a Phospholipidosis Database and Predictive Quantitative Structure-Activity Relationship (QSAR) Models. Toxicol Mech Methods 2008, 18:217-227.
21. Tatsuno M, Grossman K, Blakey RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997, 340:249-258.
22. Schneider PB, Kennedy EP: Sphingomyelinase in normal human spleens and in spleens from subjects with Niemann-Pick disease. J Lipid Res 1967, 8:202-209.
23. Smalla B, Barone L, Valentin JP, Pollard C, Ciaccio P: A comparison between compound potency in an in vitro phospholipidosis assay and at the hERG-encoded potassium channel. J Pharmacol Toxicol Methods 2007, 56:e70.
24. Ryfeldt A: Drug-induced inflammatory responses to the lung. Toxicol Lett 2000, 112-113:171-176.

doi:10.1186/1758-2946-4-2
Cite this article as: Lowe et al: Predicting the mechanism of phospholipidosis. Journal of Cheminformatics 2012 4:2.